Atai Life Sciences, the German startup aiming to develop mental health treatments using psychedelic substances, has raised a $157 million round.
- The Series D was led by Atai founder Christian Angermayer's family office Apeiron Investment Group, Peter Thiel's Thiel Capital and Woodline Partners.
- The new funding values the company at around $2 billion, Bloomberg reported. Atai is also reportedly set to tap banks for a potential US public listing as soon as Q2.
- Last November, Atai secured $125 million for its Series C.
- The company is developing and acquiring treatments for disorders like anxiety, depression and addiction.